Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1993 Sep;68(3):559-67.
doi: 10.1038/bjc.1993.386.

A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects

L T Vlasveld  1 , A Hekman, F A Vyth-Dreese, E M Rankin, J G Scharenberg, A C Voordouw, J J Sein, T A Dellemijn, S Rodenhuis, C J Melief
Affiliations
Free PMC article
Clinical Trial

A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects

L T Vlasveld et al. Br J Cancer. 1993 Sep.
Free PMC article

Abstract

Previously we described the clinical aspects of a phase I study of prolonged continuous infusion of low-dose recombinant interleukin-2 (rIL-2). In the present paper we report several immunological effects in 13 patients with melanoma and renal cell cancer treated on an out-patient basis with rIL-2 for uninterrupted periods ranging from 5 to 18 weeks. Groups of three patients were treated at following dose levels 0.18, 0.6, 1.8 or 6 x 10(6) IU m-2 24 h-1 and one patient was treated with 3 x 10(6) IU m-2 24 h-1. Prolonged rIL-2 treatment resulted in a dose-dependent and sustained increase in the percentage and absolute number of (CD56+, CD8dim) natural killer cells. Within this population a preferential increase in the CD56bright cells with low expression of CD16 was observed. The CD27 antigen was also upregulated in the CD56bright CD16dim population. This increase of NK cells was accompanied by an enhancement of the cytotoxic capacity of the peripheral lymphocytes. No consistent signs of T cell activation or expansion were noted.

PubMed Disclaimer

Comment in

  • Prolonged continuous infusion of low-dose rIL-2.
    Janssen RA, Buter J, The TH, Mulder NH, de Leij L. Janssen RA, et al. Br J Cancer. 1994 May;69(5):976-7. doi: 10.1038/bjc.1994.189. Br J Cancer. 1994. PMID: 8180034 Free PMC article. No abstract available.

References

    1. J Exp Med. 1989 Apr 1;169(4):1323-32 - PubMed
    1. J Clin Oncol. 1989 Feb;7(2):276-84 - PubMed
    1. J Immunol. 1989 Apr 15;142(8):2949-54 - PubMed
    1. Cancer Res. 1989 Jul 1;49(13):3680-8 - PubMed
    1. Cancer Immunol Immunother. 1989;29(4):261-9 - PubMed

Publication types

MeSH terms